文献速递新发突发、热带与寄生虫病

恶性疟治疗后间日疟原虫血症风险的系统综述与荟萃分析

Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis.
PubMed 文献 · Lancet Infect Dis · 2019-01-01

BACKGROUND: A 14-day course of primaquine is used for radical cure of Plasmodium vivax and Plasmodium ovale malaria only. We quantified the risk of P vivax parasitaemia after treatment of Plasmodium falciparum with commonly used antimalarial drugs to assess the potential benefits…

核心结论

  • 恶性疟治疗后间日疟原虫血症风险较高,尤其在短复发周期地区和快速消除类ACT治疗后。
  • 在共流行区,对所有无并发症疟疾患者普遍根治可能大幅减少复发性疟疾。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、Web of Science和Cochrane系统综述数据库。
  • 纳入1960年1月1日至2018年1月5日发表的前瞻性临床研究,评估无并发症恶性疟患者药物疗效。
  • 130项(85%)研究来自亚太地区,16项(10%)来自美洲,7项(5%)来自非洲。

主要发现

  • 含甲氟喹或哌喹的ACT方案较蒿甲醚-苯芴醇延迟复发性原虫血症,但至第63天所有评估ACT方案间日疟原虫血症风险均超过15%。

关键数值与推荐

  • 主要结局为恶性疟抗疟治疗开始后第7至42天间日疟原虫血症风险,采用随机效应荟萃分析计算汇总风险。
  • 比较不同以青蒿素为基础的联合疗法(ACT)治疗后间日疟原虫血症风险。
  • 研究注册于PROSPERO,注册号CRD42017064838。

临床怎么用

  • 在间日疟与恶性疟共流行区,应关注恶性疟治疗后间日疟原虫血症风险。
  • 短复发周期地区及使用快速消除类ACT后风险更高,可考虑普遍根治策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A 14-day course of primaquine is used for radical cure of Plasmodium vivax and Plasmodium ovale malaria only. We quantified the risk of P vivax parasitaemia after treatment of Plasmodium falciparum with commonly used antimalarial drugs to assess the potential benefits of radical cure for all patients with uncomplicated malaria in co-endemic regions. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, Web of Science, and the Cochrane Database of Systematic Reviews for prospective clinical studies in any language, published between Jan 1, 1960, and Jan 5, 2018, assessing drug efficacy in patients with uncomplicated P falciparum malaria in countries co-endemic for P vivax. Studies were included if the presence or absence of P vivax parasitaemia was recorded after treatment. The primary outcome was the risk of P vivax parasitaemia between day 7 and day 42 after initiation of antimalarial treatment for P falciparum, with the pooled risk calculated by random-effects meta-analysis. We compared the risk of P vivax parasitaemia after treatment with different artemisinin-based combination therapies (ACTs). This study is registered with PROSPERO, number CRD42017064838. FINDINGS: 153 of 891 screened studies were included in the analysis, including 31 262 patients from 323 site-specific treatment groups: 130 (85%) studies were from the Asia-Pacific region, 16 (10%) from the Americas, and seven (5%) from Africa. The risk of P vivax parasitaemia by day 42 was 5·6% (95% CI 4·0-7·4; I2=92·0%; 117 estimates). The risk of P vivax parasitaemia was 6·5% (95% CI 4·6-8·6) in regions of short relapse periodicity compared with 1·9% (0·4-4·0) in regions of long periodicity, and was greater after treatment with a more rapidly eliminated ACT: 15·3% (5·1-29·3) for artemether-lumefantrine compared with 4·5% (1·2-9·3) for dihydroartemisinin-piperaquine and 5·2% (2·9-7·9) for artesunate-mefloquine. Recurrent parasitaemia was delayed in patients treated with ACTs containing mefloquine or piperaquine compared with artemether-lumefantrine, but by day 63 the risk of vivax parasitaemia was more than 15% for all ACTs assessed. INTERPRETATION: Our findings show a high risk of vivax parasitaemia after treatment of falciparum malaria, particularly in areas with short relapse periodicity and after rapidly eliminated treatment. In co-endemic regions, universal radical cure for all patients with uncomplicated malaria has the potential to substantially reduce recurrent malaria. FUNDING: Australian National Health and Medical Research Council, Royal Australasian College of Physicians, Wellcome Trust, and Bill & Melinda Gates Foundation.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Commons RJ, Simpson JA, Thriemer K, et al. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis. 2019. PMID: 30587297. doi:10.1016/S1473-3099(18)30596-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。